Evidence map›Paper›PMID 36212452›Full record

ArticleFrontiers in oncology2022

A distinct subpopulation of leukemia initiating cells in acute precursor B lymphoblastic leukemia: quiescent phenotype and unique transcriptomic profile.

Alex Q Lee, Hiroaki Konishi, Connie Duong, Sakiko Yoshida, Ryan R Davis, Jonathan E Van Dyke, Masami Ijiri, Bridget McLaughlin, Kyoungmi Kim, Yueju Li and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Alex Q LeeDepartment of Pediatrics, University of California (UC) Davis School of Medicine, Sacramento, CA, United States.
Hiroaki KonishiDepartment of Pediatrics, University of California (UC) Davis School of Medicine, Sacramento, CA, United States.
Connie DuongDepartment of Pediatrics, University of California (UC) Davis School of Medicine, Sacramento, CA, United States.
Sakiko YoshidaDepartment of Pediatrics, University of California (UC) Davis School of Medicine, Sacramento, CA, United States.
Ryan R DavisGenomics Shared Resource, University of California (UC) Davis Comprehensive Cancer Center, Sacramento, CA, United States.
Jonathan E Van DykeFlow Cytometry Shared Resource, University of California (UC) Davis Comprehensive Cancer Center, Sacramento, CA, United States.
Masami IjiriDepartment of Pediatrics, University of California (UC) Davis School of Medicine, Sacramento, CA, United States.
Bridget McLaughlinFlow Cytometry Shared Resource, University of California (UC) Davis Comprehensive Cancer Center, Sacramento, CA, United States.
Kyoungmi KimDepartment of Public Health Sciences, Division of Biostatistics, University of California (UC) Davis, Davis, CA, United States.
Yueju LiDepartment of Public Health Sciences, Division of Biostatistics, University of California (UC) Davis, Davis, CA, United States.
Laurel BeckettDepartment of Public Health Sciences, Division of Biostatistics, University of California (UC) Davis, Davis, CA, United States.
Nitin NitinDepartments of Food Science & Technology and Biological & Agricultural Engineering, University of California (UC) Davis, Davis, CA, United States.
John D McPhersonGenomics Shared Resource, University of California (UC) Davis Comprehensive Cancer Center, Sacramento, CA, United States.
Clifford G TepperGenomics Shared Resource, University of California (UC) Davis Comprehensive Cancer Center, Sacramento, CA, United States.
Noriko SatakeDepartment of Pediatrics, University of California (UC) Davis School of Medicine, Sacramento, CA, United States.
University of California, Davis · USUC Davis Comprehensive Cancer Center

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
UC Davis Environmental Health Sciences Core CenterP30ES023513 · NIEHS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Ameer Taha · 2015 to 2026
$26.0M
NCI NIH HHS P30 CA093373NIEHS NIH HHS P30 ES023513
6 · The paper itself

Abstract

In leukemia, a distinct subpopulation of cancer-initiating cells called leukemia stem cells (LSCs) is believed to drive population expansion and tumor growth. Failing to eliminate LSCs may result in disease relapse regardless of the amount of non-LSCs destroyed. The first step in targeting and eliminating LSCs is to identify and characterize them. Acute precursor B lymphoblastic leukemia (B-ALL) cells derived from patients were incubated with fluorescent glucose analog 2-(N-(7-Nitrobenz-2-oxa-1, 3-diazol-4-yl) Amino)-2-Deoxyglucose (NBDG) and sorted based on NBDG uptake. Cell subpopulations defined by glucose uptake were then serially transplanted into mice and evaluated for leukemia initiating capacity. Gene expression profiles of these cells were characterized using RNA-Sequencing (RNA-Seq). A distinct population of NBDG-low cells was identified in patient B-ALL samples. These cells are a small population (1.92% of the entire leukemia population), have lower HLA expression, and are smaller in size (4.0 to 7.0 μm) than the rest of the leukemia population. All mice transplanted with NBDG-low cells developed leukemia between 5 and 14 weeks, while those transplanted with NBDG-high cells did not develop leukemia (p ≤ 0.0001-0.002). Serial transplantation of the NBDG-low mouse model resulted in successful leukemia development. NBDG-medium (NBDG-med) populations also developed leukemia. Interestingly, comprehensive molecular characterization of NBDG-low and NBDG-med cells from patient-derived xenograft (PDX) models using RNA-Seq revealed a distinct profile of 2,162 differentially-expressed transcripts (DETs) (p<0.05) with 70.6% down-regulated in NBDG-low cells. Hierarchical clustering of DETs showed distinct segregation of NBDG-low from NBDG-med and NBDG-high groups with marked transcription expression alterations in the NBDG-low group consistent with cancer survival. In conclusion, A unique subpopulation of cells with low glucose uptake (NBDG-low) in B-ALL was discovered. These cells, despite their quiescence characteristics, once transplanted in mice, showed potent leukemia initiating capacity. Although NBDG-med cells also initiated leukemia, gene expression profiling revealed a distinct signature that clearly distinguishes NBDG-low cells from NBDG-med and the rest of the leukemia populations. These results suggest that NBDG-low cells may represent quiescent LSCs. These cells can be activated in the appropriate environment

Indexed as

B-ALLglucoseleukemia initiating capacityleukemia initiating cellsmetabolic activitytranscriptome profiling

Identifiers

PMID36212452
PMCPMC9533407
OpenAlexW4296538758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.